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ABSTRACT 
Activity landscape modelling is mostly a descriptive technique that allows rationalizing 
continuous and discontinuous SARs, however the interpretation, especially of activity cliffs, is 
not straightforward. As the nature of activity cliffs depends on the ligand and the target, 
information regarding both should be included in the analysis. A specific way to include this 
information is using protein-ligand interaction fingerprints (IFPs). In this paper we report the 
activity landscape modelling of 507 ligand-kinase complexes (from KLIFS database) adding IFP, 
which facilitates the analysis and interpretation of activity cliffs. To this end, we introduce the 
structure-activity-interaction similarity (SAIS) maps that incorporate information of ligand-target 
contact similarity. We also introduce the concept of interaction cliffs defined as ligand-target 
complexes with high structural and interaction similarity, but a large potency difference of the 
ligands. Moreover, the specific interaction information allowed the identification of activity cliff 
hot spots, which help to rationalize activity cliffs from the target point of view. In general, the 
information provided by IFPs helps to get a better understanding when modelling an activity 
landscape. This paper shows examples of analyses that can be carried out when IFPs are added to 
the activity landscape model. 
Keywords: Activity landscape, Activity cliffs, Interaction cliffs, Protein-ligand interaction 
fingerprints, Kinase inhibitors, SAS maps.   
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INTRODUCTION 
The analysis of structure-activity relationships (SARs) is a fundamental tool to understand and 
design new bioactive molecules. In this context, activity landscape modelling arises as a 
descriptive technique that allows to rationalize continuous and discontinuous SARs, but also 
helps to systematically analyse and characterize large data sets.1 An activity landscape is defined 
as “biological response surfaces in chemical space that are obtained by adding an activity 
dimension to this space”2 or as “any representation that integrates the analysis of the structural 
similarity and potency differences between compounds sharing the same biological activity”.1 
Numerous methods have been proposed to study the activity landscape of large datasets, for 
example structure-activity similarity (SAS) maps,3, 4 structure multiple-activity similarity 
(SmAS) maps,5 dual and triple activity difference (DAD/TAD) maps,6, 7 and network-like 
similarity graphs (NSG)8 to name a few (more methods have been reviewed9 recently). 
Moreover, activity landscape modelling is suitable for the identification of activity cliffs, which 
are defined as a pair of structurally similar molecules that have large changes in potency.10, 11 
Despite the fact that activity landscape modelling has been extensively used to characterize 
different target12-14 and multitarget5, 15, 16 data sets, the interpretation of the activity landscape, 
especially for activity cliffs, is not straightforward.17 In order to rationalize the formation of 
activity cliffs our group has used molecular docking18 and the concept of activity cliff 
generators19 to explore the causes associated with the potency difference. Other attempts to 
rationalize activity cliffs include the concepts of structure-based activity cliffs and activity cliff 
hot spots proposed by Seebeck et al., which evaluate the frequency with which a protein atom is 
involved in the formation of an activity cliff taking into account the interaction energies of 
protein-ligand complexes.20  
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As the nature of an activity cliff depends on the ligand and target, whenever possible, 
information regarding both should be included in the analysis. One way to accomplish this is to 
include explicit information regarding the target (i.e. sequences and sequence similarities) as 
previously reported for a set of kinase inhibitors.16 A more specific alternative is to capture 
information of how the ligand interacts with the protein, for example, using molecular interaction 
fingerprints (IFPs) of protein-ligand complexes. IFPs conveniently simplify the interactions 
between proteins and ligands by coding them in a 1D representation.21, 22 IFPs have been 
successfully used for post-processing of ligand docking poses according to known interaction 
patterns for protein targets in structure-based virtual screening studies23, 24 and allow systematic 
mining of protein-ligand interaction space to identify conserved and selective protein interaction 
hot spots.25-27 In this work we report an approach to integrate IFPs in the activity landscape 
modelling process, in order to identify regions in the target protein that are associated with 
activity cliffs. This method is particularly useful when analysing a large number of ligand-target 
complexes, given that it does not require of large amount of computing time or resources. We 
also introduce the structure-activity-interaction (SAIS) maps, which are a natural extension of 
the SAS maps initially developed to characterize the SAR of screening data sets. The use of IFPs 
facilitates the analysis of activity cliffs and the identification of scaffold hops. Moreover, adding 
specific interaction information allowed the identification of activity cliff hot spots, which help 
to gain a deeper insight in the formation of activity cliffs. To exemplify the approach, we 
analysed KLIFS, a recently developed and publicly available database that has information of 
1,734 crystallographic structures covering 190 human kinases.27 It is important to mention that 
this paper demonstrates only some of the analyses that can be carried out when IFPs are added to 
the activity landscape model. Another example is the analysis that was published by Furtmann et 
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al.,28 which was published during the final preparations of this study.  They have analysed 3D-
cliffs using this same data set, denoting the interest of the scientific community in using crystal 
structures for activity landscape modelling.  
MATERIALS AND METHODS 
Data set 
The structural data used in this study was extracted from KLIFS.27 KLIFS is a curated database 
that contains 1,734 aligned crystal structures, covering 190 different human kinases, from which 
1,252 are co-crystalized with a ligand. In order to facilitate the analysis of the crystal structures 
present in KLIFS, the ligands and the binding pockets (containing 85 amino acids) were 
separated in this database. More detailed information regarding the curation, alignment and 
preparation of KLIFS can be found elsewhere.27 It should be noted that the pocket residue 
numbering and nomenclature reported in the KLIFS publication is used throughout this 
manuscript.  
All experimental binding data was extracted from Binding MOAD database,29, 30 which 
contains information from the primary reference of each PDB entry. Using this database, 409 out 
of the 1,252 KLIFS entries were annotated with pIC50 values (ranging from 3 to 10.52), pKi 
values were found for 70 complexes (4.46 - 9.96) and 28 structures were annotated with pKd 
values (4.43 - 8.68). It is noteworthy that the wide activity range presented in these data sets 
make them suitable for activity landscape analysis and activity cliffs detection. These three data 
sets were used for further analysis. 
Structure, activity and interaction similarity 
Same as in previous studies,7, 19 a set of eleven broadly used 2D fingerprints was calculated for 
these datasets with MayChemTools.31 These fingerprints include atom neighbourhoods,32 atom 
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types, electrotopological state indices (EStateIndices),33 extended connectivity (ECFP4),34 
MACCS (322 bits),35 path length, topological atom pairs (TopAtomPairs),36 topological atom 
torsions (TopAtomTorsions),37 topological atom triplets (TopAtomTriplets), topological 
pharmacophore atom pairs (TopPh4Pairs),38 and topological pharmacophore atom triplets 
(TopPh4Triplets).39 The Tanimoto coefficient40-42 was employed to assess the structural 
similarity using each of these 2D descriptors. ComboScore, computed with the Rapid Overlay of 
Chemical Structures (ROCS) module of OpenEye Scientific Software,43 was also used to 
evaluate the 3D similarity among the different compounds. To compute the 3D similarity, the 
coordinates of the bioactive conformation of each ligand were taken from each crystal structure 
and used to calculate ComboScore as implemented in ROCS. In order to maintain the same range 
in molecular similarity measurements (0 to 1) across all fingerprints, ComboScore similarity was 
scaled dividing it by two. Although this is a purely ligand-based approach, the information of 
ligand positions in the binding pocket is encoded in the IFP of each compound (see below). 
Potency differences were used to assess the activity relationship between two compounds. 
Activity differences were calculated as follows: |∆!"(R)!,!| = ! !"(R)! − !"(R)!  
where pA(R)i and pA(R)j are the activities (pIC50, pKi and pKd) of the ith and jth molecules (j 
> i) against each receptor R. In this paper R can be the same or different kinase. 
Interaction similarity was assessed using IFPs extracted from KLIFS for each complex used in 
this study. IFPs in these datasets were calculated using the interaction fingerprints developed by 
Marcou and Rognan,44 encoding seven types of interactions for each amino acid i.e. seven binary 
bits per amino acid depending if the interaction is present or absent. The seven bits correspond to 
the following interactions: hydrophobic contact, face-to-face aromatic interactions, face-to-edge 
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aromatic interactions, protein H-bond donor, protein H-bond acceptor, protein cationic 
interactions, protein anionic interactions (calculation details are listed in Table S1). A total of 
595 bits were obtained for each complex corresponding to the 85 aligned residues that form the 
ATP binding pocket as defined by van Linden et al.27 The interaction similarity between two 
complexes was also calculated using the Tanimoto coefficient,40-42 although other similarity 
measures can be used as well. 
Activity landscape modelling 
In this study, SAIS maps were developed to analyse the multitarget activity landscape of these 
data sets. In a SAIS map, which is based on the structure of the SAS maps, each point represents 
a pairwise comparison between two protein-ligand complexes, localized by plotting the structure 
similarity between the two ligands in the X-axis against the absolute potency difference in the Y-
axis. Data points are color-coded by protein-ligand interaction similarity using a continuous scale 
from more similar (red) to less similar (green). Similar to SAS maps,4, 14, 45, 46 SAIS maps can 
analyse the multitarget activity landscape against one or more targets as they incorporate protein 
information through the measure of interaction similarity. This approach is similar to other 
multitarget methods in which explicit protein information is given by sequence similarity,16 
however the use of interaction similarity allows the identification of important amino acids for 
the formation of activity cliffs. 
SAIS maps can be roughly divided in four different regions, namely regions I-IV. Region I 
contains pairs of molecules that have low potency difference and low structural similarity, thus 
they are generally considered as scaffold hops.47 Data points located in region II are 
characterized by similar activity (low potency difference) and high structural similarity; therefore 
these pairs of compounds present continuous SARs. Region III contains data pairs with different 
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structures and low potency similarity (large potency difference). Finally, pairs of molecules 
located in region IV exhibit a discontinuous SAR denoted by high structural similarity, but high 
potency difference and therefore are associated with activity cliffs.  
The activity landscape characterization, as described before, was achieved by dividing each 
plot using potency difference and structure similarity thresholds along the Y- and X-axis, 
respectively.19 An additional threshold was used for the interaction similarity in order to identify 
differences in the binding modes. In this work, a threshold of 1 log unit of absolute difference 
was used to distinguish between compounds with high and low potency difference. However, 
assigning a threshold for structural similarity is not straightforward as different criteria to impose 
thresholds can be employed.4, 48 In this work, the thresholds for structural and interaction 
similarity were set as the mean similarity value plus two standard deviations and were calculated 
individually for each data set. A graphical representation of the density distribution for each data 
set is shown in Figure 1. 
Figure 1. Density distribution of structural and interaction similarity for the three data sets 
(pIC50, pKi, pKd) used in this study evaluating 83,436, 2,415 and 378 molecular pairs, 
respectively. The mean values of structure and interaction similarity for these data sets (using 
ComboScore/2 and IFPs, respectively) are shown with continuous lines.  
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RESULTS AND DISCUSSION 
Activity landscape modelling 
Figures 2A-C show the SAIS maps for each of the three data sets used in this study (pIC50, 
pKi, pKd) containing 83,436, 2,415 and 378 points, respectively, and Table 1 summarizes the 
distribution of the data points in each region. These maps encode the relationships between the 
3D binding conformation of the ligands, how they interact with the target, and the associated 
biological activity. In general, ligands in all data sets have different binding conformations 
represented by low structural similarity values. Figure 1 shows that the mean structural similarity 
in the three data sets, represented here by the ComboScore/2 value, ranges from 0.366 to 0.383. 
This low structural similarity is accompanied of large potency differences, even reaching 7.5 log 
units of difference. Because of these structural and potency differences, more than 50% of all the 
data points are located in region III of the three SAIS maps (Table 1). This distribution and the 
low structural similarity are associated with the large size and flexibility of the ATP binding site 
in kinases, which is able to accommodate very diverse compounds (e.g. type I and type II 
inhibitors) that bind to different subregions within the ATP binding site. The remaining data 
points are distributed in the following manner: region I comprises around 40% of data points, 
whereas region II and IV only contain less than 2% each. As expected, data points in region IV 
(activity cliffs) represent a small fraction of all pairs in SAIS maps, although it is known that this 
region provides the most information on SARs.46  
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Table 1. Distribution of data points across different regions of the SAIS maps generated for the 
three datasets. The percentage of points in each region is indicated in parenthesis. 
Dataset Protein-
Ligand 
structures 
Molecular 
pairs 
Ligand 
structure 
similarity 
thresholda 
 I II III IV 
pIC50 409 83,436 0.563  
32,749 
(39.25%) 
1,276 
(1.53%) 
47,948 
(57.47%) 
1,463 
(1.75%) 
pKi 70 2,415 0.563  
833 
(34.49%) 
35 
(1.45%) 
1,512 
(62.61%) 
35 
(1.45%) 
pKd 28 378 0.569  
164 
(43.39%) 
5 
(1.32%) 
201 
(53.17%) 
8 
(2.12%) 
aLigand structure similarity is calculated using ComboScore as implemented in ROCS 
As discussed before,49 chemical space, and hence activity landscape models, is highly 
dependent from the chemical representation used to describe molecules. In contrast with the 
strategy used in previous work where the combination of different molecular representation was 
needed (consensus activity landscapes),7, 19, 48, 49 here, only the 3D similarity (i.e. the 
ComboScore, which combines shape and pharmacophore similarity) was used due to the 
availability of the bioactive 3D conformation of the ligands, although 3D techniques other than 
ROCS could have been used in addition as well. Tables S2-S4 show matrices with Pearson’s 
correlation coefficients between all the pairwise similarities for each molecular representation 
used in this study. The ComboScore showed low correlation (<0.55) with the scores obtained 
from the other eleven 2D fingerprints used to assess molecular similarity in all data sets. 
Interestingly, the scores from the Extended Connectivity (in pIC50) and AtomNeighborhoods (in 
pKi and pKd) presented the highest correlation with the ROCS ComboScore with correlation 
coefficients of 0.243, 0.408 and 0.530 for pIC50, pKi and pKd data sets, respectively. This low 
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correlation suggests that the 2D descriptors computed in this work would not be appropriate to 
capture information related to 3D conformations, such as different binding poses that could be 
related to a particular interaction profile between the ligand and the target protein.  
Figure 2. Panels A-C show Structure-Activity-Interaction Similarity (SAIS) maps for the three 
datasets used in this study (pIC50, pKi and pKd) containing 83,436, 2,415 and 378 data points, 
respectively, resulting from the pairwise comparisons. Data points are color-coded by interaction 
similarity using a continuous scale from red for very similar interactions to green for molecular 
pairs that form different interactions with the target. Regions (I-IV) are labelled in each SAIS 
map. Panels D-F highlight in red those molecular pairs with high interaction similarity, that is, 
two standard deviations above mean similarity for each data set. Detailed information can be 
found in Table 2. 
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Interaction cliffs 
Interaction similarity calculated using the IFPs as a representation of protein-ligand 
interactions, was used in order to gain a deeper understanding at the structural level of the 
activity cliffs present in these data sets. Alike to structural similarity, the three data sets also 
exhibit low interaction similarity, with mean values ranging from 0.384 to 0.425. Despite the 
analogous distribution in both measures, a very low correlation (< 0.45) was found between 
interaction similarity and structural similarity. It is worth mentioning that ComboScore showed 
the highest correlation with interaction similarity in all data sets compared to the 2D descriptors 
(Tables S2-S4). The lack of correlation between ligand and interaction similarities has been 
observed in large-scale studies reported before, but it has also been noted that interaction 
similarity can be correlated with binding site similarity.21  
Figures 2D-F show the three SAIS maps highlighting those molecular pairs with high 
interaction similarity relative to the data set, that is, two standard deviations above the 
corresponding mean similarity for each data set. As depicted in these figures, not only those 
compounds with high molecular similarity show high interaction similarity, but also those 
molecular pairs with different chemical structures can present similar ligand-target interactions. 
On average, only 33% of the molecular pairs categorized as highly similar (regions II and IV) 
showed similar interactions. Moreover, most of the compounds with high interaction similarity 
are located in regions I and III, which can be related to scaffold hops (as they can retain the same 
pharmacophore even presenting different shape/conformation). Details regarding the distribution 
of molecular pairs with high interaction similarity can be found in Table 2. Interestingly, less 
than 40% of the pairs located in region IV present high interaction similarity, suggesting that 
high similar compounds do not always interact in a similar manner with the binding site of 
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different kinases. Those pairs of ligands that present high structural and high interaction 
similarity, but also a large potency/affinity difference (i.e. activity cliffs with high interaction 
similarity) can provide information regarding the specific interactions or chemical features that 
are directly associated with the increase or decrease of potency and will be referred to as 
interaction cliffs from now on in this work. 
 
Table 2. Distribution of data points with high interaction similarity across different regions of 
the SAIS maps. The percentage of points in each region is indicated between parentheses. 
Dataset Interaction 
similarity 
thresholda 
Molecular 
pairs 
 I II III IV 
pIC50 0.674 83,436  838 (1.00%) 372 (0.45%) 959 (1.15%) 280 (0.34%) 
pKi 0.652 2,415  29 (1.20%) 14 (0.58%) 22 (0.91%) 7 (0.29%) 
pKd 0.680 378  11 (2.91%) 3 (0.79%) 4 (1.06%) 3 (0.79%) 
aInteraction similarity is calculated by Tanimoto similarity of IFPs 
It is noteworthy that 80% of the interaction cliffs in the pIC50 data set include crystal structures 
of kinases in two different branches of the kinome, namely CMGC and TK. From the 280 
interaction cliffs, 136 are formed by two complexes of the CMGC group, 51 include two 
complexes of the TK group and 36 by one complex of the CMGC and one of the TK group. It is 
important to mention that this high percentage is influenced by the number of crystal structures 
with kinases from these groups (177 and 109 for CMGC and TK, respectively). In the cases 
where the interaction cliffs are formed by two complexes involving the same kinase, the amino 
acid sequences are identical in both proteins and thus, the interaction and potency differences are 
caused mainly by small structural differences in the ligand that can form new interactions with 
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the target. On the other hand, when interaction cliffs are formed by complexes containing kinases 
from different groups (or protein with low sequence similarity), then the potency and interaction 
difference could also be caused by changes in the target sequence, and thus protein structure, that 
impact ligand binding.  
In order to compare this multitarget study with an equivalent single target approach we 
generated a SAIS map with 97 ligand-CDK2 complexes from the pIC50 dataset (Figure S1). This 
SAIS maps contains 4,656 pairwise comparisons, but only 691 of them with high interaction 
similarity. Interestingly, the Pearson correlation between the interaction and structural similarity 
was 0.383 for these CDK2 complexes. This represents a slightly increment compared to the same 
correlation including all the pIC50 data points (which leads to a value of 0.369). In general, the 
low correlation is caused by pairs of ligand-target complexes in which the structural similarity is 
lower than the interaction similarity; in other words, different ligands that maintain similar or 
key interactions with the target. Another differences between the single and the multitarget 
approach is the fraction of activity cliffs that also are interaction cliffs. For instance, for the 
CDK2 complexes we identified 267 activity cliffs from which 119 correspond to interaction 
cliffs (44.6%), whereas in the complete pIC50 dataset we found 1,463 activity cliffs and only 280 
interaction cliffs (including the 119 of CDK2). However, this difference is not caused by an 
increased number of interaction cliffs, but can be ascribed to a decreased number of activity cliffs 
with low interaction similarity. 
 
Interpretation of activity and interaction cliffs 
Figure 3 shows examples of activity and interaction cliffs in the three data sets. As mentioned 
above, the inclusion of interaction similarity facilitates the analysis of activity cliffs and helps to 
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find specific characteristic in the compounds or targets that can drive to more active or selective 
compounds. From the 280 interaction cliffs found in the data set with pIC50 values, pair 
2WMR_2X8E is a representative example of similar compounds (ComboScore/2 value of 0.79) 
that form almost the same interactions with the binding site (interaction similarity of 0.714), but 
present a potency difference of more than 3.5 log units. Figure 3A shows that in the complex 
2WMR the pyrimidinone moiety of 1 forms a hydrogen bond with the E85hinge.46 and C87hinge.48 
amino acids located in the hinge area of CHK1 and also has hydrophobic contact with the 
gatekeeper amino acid L84GK.45 (Figure 3D).50 The same hydrogen bonds are present in the 
complex 2X8E by the triazolone of 2, but in this complex the 4-pyridyl ring is located in the 
solvent channel of the kinase domain forming hydrophobic interactions with S88linker.49 and 
G89linker.51.51 This difference helps to provide a structure-based hypothesis of the very large 
potency difference.  
Another example of an interaction cliff in this data set is pair 2HYY_3HEC (Figure 3B), 
which contain the same kinase inhibitor (imatinib 3) bound to ABL1 and p38α, respectively. 
Despite the fact that both crystal structures contain the same ligand, the interaction similarity of 
this pair is 0.75 and present a potency difference of 2.6 log units. In both crystal structures 
imatinib forms hydrogen bonds between the pyrimidine and the main chain of Mhinge.48, the NH 
linker with the TGK.45, and the amide moiety of 3 with the side and main chains of EαC.24 and 
DxDFG.81, respectively. In addition to these interactions, the complex with ABL1 (2HYY)52 
presents an extra hydrogen bond between the piperazine of 3 and the backbone of I360VI.67, and 
face-to-face π stacking with the F317hinge.47. Figure 3D also shows that imatinib forms more 
hydrophobic interactions in 2HYY compared to 3HEC, which reflects the variation in solvent 
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accessible surface area reported for ligand bound to ABL1 and p38α (35.4 and 89.6 Å, 
respectively) that correlates with the potency difference.53 
Figure 3C shows an example of activity cliff in the same data set with pIC50 values. Inhibitors 
4 and 5 that form the pair 2R3J_2C69 have very high structural similarity (ComboScore/2 value 
of 0.83) and a large potency difference of 3.4 log units against CDK2, however the interaction 
similarity (0.652) is lower than the threshold used to identify interaction cliffs. In this case, 
differences in interaction patterns are mainly caused by the hydrophobic contacts between the 5-
bromophenyl group of 4 and E12g.l.5 as well as the hydrogen bond formed between the 
pyrazolopyrimidine moiety of 4 and the basic amine group of K33III.17 in 2C69, that is not formed 
with pyrazolopyrimidine 5 in 2R3J.54 Previous studies have shown that the cavity that accepts 
the 5-bromophenyl and the 5-phenyl present in these compounds is large enough to contain 
bulky substituents.55 However, experimental data suggest that the bromide at position 3 of the 
pyrazolopyrimidine of 5 is responsible of the potency difference as it fills a small hydrophobic 
cavity formed at the back of the gatekeeper amino acid (F80GK.45).55  
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Figure 3. 3D representation and activity data for representative kinase-ligand complexes that 
form activity and interaction cliffs in the data set with pIC50 values: (A) Pyrimidininone 150 and 
triazolone 251 with CHK1; (B) Imatinib 3 with ABL152 and p38α53; (C) pyrazolopyrimidines 454 
and 555 with CDK2. Panel D shows the number of interactions between the ligand and each of 
the 85 amino acids in the binding site numbered as defined in KLIFS.27 Per residue, the total 
number of interacting bits is reported and color-coded according to (the combination of) 
interaction feature(s). The position of each pair in SAIS maps is depicted in Figure 2D.  
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Figures 4A and 4B depict two representative examples of the seven interaction cliffs identified 
in the data set with pKi values. The first example (Figure 4A) shows the kinase inhibitor 
Tozasertib (VX-680) 6 bound to two different kinases, namely aurora kinase (AURKA) and a 
mutant of cAMP-dependent protein kinase (PKACα). In both crystal structures, 6 forms the same 
hydrogen bond interactions with the two targets, AURKA (PDB ID: 3E5A)56 and PKACα (PDB 
ID: 3AMB).57 Nevertheless, the π-staking interaction with F144g.l.8 and hydrophobic contacts 
with two more amino acids (G140g.l.4 and L194b.l.36) in the binding site of AURKA increase the 
potency by two log units. This result highlights the importance of Fg.l.8 for the binding of 
Tozasertib, which can be considered as a “hot spot” to take into account during the design of new 
AURKA inhibitors.  
Figure 4B depicts another example of an interaction cliff, corresponding to the pair 
2ZB1_3D7Z (7 and 8). In this case, two similar compounds (ComboScore/2 = 0.82) bind to p38α 
with a similar binding mode (interaction similarity of 0.741), but with large potency difference 
(1.6 log units). The only difference between ligands 7 and 8 is the substitution of the oxadiazol 
ring in 2ZB158 by a (N-cyclopropyl)carboxamide in 3D7Z.59 This structural change disturbs the 
hydrogen bonding pattern with p38α, that is, whereas inhibitor 7 in 2ZB1 forms hydrogen bonds 
with the backbones of D168xDFG.81 and F169xDFG.82 of the DFG motif, the compound 8 in 3D7Z 
forms hydrogen bonds with backbone of D168xDFG.81 and with the carboxylate moiety of E71αC.24 
resulting in an increased potency. In addition, the cyclopropyl group in 3D7Z increases the 
number of hydrophobic contacts with the binding site. 
Finally, only three interaction cliffs were detected in the data set with pKd values, one of those 
is the pair 1KV1_2BAJ (9 and 10) shown in Figure 4C. This example shows two highly similar 
pyrazolourea inhibitors 9 and 10 (ComboScore/2 = 0.90) that present similar interactions (0.84) 
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with p38α, but a potency difference of 2.5 log units. The most important chemical differences 
between 9 and 10 are the methyl group on the pyrazole ring of 9 in 1KV160 versus the phenyl 
group of 10 in 2BAJ61 and the 4-chlorophenyl of 9 in 1KV1 versus the 2,3-dichlorophenyl of 10 
in 2BAJ. As observed before, a bulky group at this position increments the contacts with the 
hydrophobic portion of the side chain of E71αC.24 in the helix αC. This extra phenyl group targets 
the hydrophobic back pocket V27, 62 resulting in an increased activity against p38α.60  
Figure 4. 3D representation and activity data for representative protein-ligand complexes that 
form activity and interaction cliffs in the data sets with pKi and pKd values: (A) Tozasertib 6 with 
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PKACα57 and AURKA56; (B) Biphenyls 758 and 859 with p38α; (C) pyrazoloureas 960 and 1061 
with p38α. Panel D shows the number of interactions between the ligand and each of the 85 
amino acids in the binding site numbered as defined in KLIFS.27 Per residue, the total number of 
interacting bits is reported and color-coded according to (the combination of) interaction 
feature(s). The position of each pair in SAIS maps is depicted in Figure 2E-F. Figure S2 and 
Figure S3 show the 2D depiction of these complexes (generated using PoseViewWeb 1.97.063, 64) 
and the superposed 3D structures of these compounds extracted from the aligned crystal 
structure, respectively.  
Interaction cliff generators 
Activity cliff generators are compounds highly associated with activity cliffs in the data set 
(e.g., above two standard deviations of the mean frequency of activity cliffs) and hence present a 
high probability to form activity cliffs with other structurally similar molecules tested in the 
same assay.19 By analogy to activity cliff generators, interaction cliff generators are ligand-target 
complexes highly associated with interaction cliffs. A major difference between these two is that 
interaction cliff generators are more suitable for the analysis of multitarget activity landscapes 
since they are identified based on the ligand structure, its potency, and how it interacts with the 
target (which, to some extent, adds target information). In contrast, activity cliff generators do 
not include any information regarding to the target (only compound structure and potency) and 
are more suitable for a single-target activity landscapes. It is important to emphasize that the 
selection of cliff generators is based on comparisons with other compounds in the data set. Hence 
the larger the data set, the more reliable the generator is. In this study, the most reliable cliff 
generators are the ones present in the data set with pIC50 values, which contains information of 
409 ligand-target complexes.  
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Both activity and interaction cliff generators were identified in the three data sets and are listed 
with their statistics in Tables S5 and S6. In the pIC50 data set, 20 and 21 ligand-target complexes 
were identified as activity and interaction cliff generators, respectively. One example of 
interaction cliff generator is complex 2VWV, which forms 10 interaction cliffs. As shown in 
Table 3, 2VWV contains a low potency ligand bound to EphB4. Interestingly, the ligand in this 
complex shows high structural and interaction similarity to other ligands bound to different 
kinases.  
 
Table 3. List of ten ligand-target complexes that form interaction cliffs with the interaction cliff 
generator 2VWV (included in the list as reference). 
PDB ID Kinase 
IC50 (nM) of 
co-crystal 
ligand 
pIC50 
Difference 
Interaction 
Similarity 
Ligand 
Structure 
Similaritya 
2VWV EphB4 16000 0 1 1 
3EKK INSR 2 3.90 0.739 0.623 
3EKN INSR 2 3.90 0.714 0.607 
3CJF KDR 6.3 3.40 0.750 0.790 
3FQS SYK 41 2.59 0.889 0.879 
2NP8 Aurora A 42 2.58 0.739 0.600 
1OI9 CDK2 69 2.37 0.696 0.600 
3H3C PYK2 140 2.06 0.682 0.580 
2IW6 CDK2 140 2.06 0.696 0.597 
2C5N CDK2 220 1.86 0.714 0.670 
2C6K CDK2 730 1.34 0.680 0.610 
aLigand structure similarity is calculated using ComboScore as implemented in ROCS 
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Identification of activity cliff hot spots 
Seebeck et al. define activity cliff hot spots as those specific regions or atoms in the target 
involved in key interactions with the ligand that lead to the formation of an activity cliff.20 In this 
paper, activity cliff hot spots were identified in the pIC50 data set as the most frequent 
interactions that appear in the formation of an activity cliff. To this end, only the interactions 
presented by one of the two compounds forming the cliff were taken into account, discarding the 
interactions that are presented by both compounds in the pair. From the 595 interactions (seven 
per each of the 85 amino acids) encoded in the IFPs for this data set, only 116 were present at 
least once in the formation of activity cliffs. Hydrophobic contact was the most common 
interaction (frequency of 55), followed by cases where the amino acids are acting as hydrogen 
bond acceptors or donors (frequency of 21 and 15, respectively) or forming face-to-face/edge 
interactions (frequency of 7 and 11, respectively). The least frequent interactions were protein 
anionic and cationic interactions (frequency of five and two times, respectively).  
Table 4 lists the interactions that were present in at least 20% of the 1,463 activity cliffs in the 
pIC50 data set. This table also shows the amino acid position, the type of interaction and its 
frequency either in the most active or least active compound of the molecular pair. Among the 
most frequent amino acids interacting in activity cliffs we can find those at positions 4-6 which 
correspond to the glycine-rich loop, position 17 located in β–sheet III at the gate area, positions 
46-48 which are in the hinge region, 49-52 from the linker region and 80-81 from the xDFG 
motif. Interestingly, some of these amino acids are highly conserved, for example a glycine at 
position 4 and 6 (98% and 100%, respectively, of conservation in KLIFS structures), a lysine at 
position 17 (100%) and an aspartate at position 81 (99%).27 It is important to note that some of 
these amino acids are known to be important for ligand binding, for example the orientation of 
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DxDFG.81 side chain is commonly used (in combination with FxDFG.82 and the backbone shift) to 
define if the kinase is in an active or inactive (DFG-in or DFG-out, respectively) conformation.65 
In this analysis, the most active compound in the activity cliff usually presents a hydrophobic 
interaction with the amino acid at this position. Another example of an important residue is the 
one at position 47 in the hinge region. For this residue it is known that many compounds have a 
face-to-face/edge interaction when there is a phenylalanine at this position, however the 
interaction is lost when the kinase has a leucine or tyrosine instead. The conserved KIII.17 also 
plays a very important role in ligand binding; it forms hydrogen bonds and hydrophobic 
interactions in 37% and 41% of the activity cliffs, respectively. This conserved amino acid, 
KIII.17, commonly forms a hydrogen bond with DFG-out binders, which are known to present 
improved selectivity and slower dissociative off-rate.66 It is important to mention that no direct 
effect or influence of DFG-in or DFG-out target conformations was observed in these activity 
cliffs. 
 
Table 4. List of most frequent interactions involved in the formation of at least 20% of activity 
cliffs. The total frequency is further divided in two parts to distinguish if the interaction is more 
frequent in the most active or least active compound of the molecular pair. 
Amino acid 
position in 
KLIFS27 
Type of 
interactiona 
Percentage of 
activity cliffs 
Frequency 
Total Most active compound 
Least active 
compound 
xDFG.81 HYD 45.73 669 515 154 
hinge.47 FF 41.63 609 348 261 
linker.50 HYD 41.63 609 256 353 
linker.51 HYD 40.53 593 385 208 
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III.17 HYD 40.46 592 340 252 
linker.52 HYD 40.33 590 314 276 
g.l.4 HYD 39.30 575 375 200 
xDFG.80 HYD 36.98 541 323 218 
III.17 DON 36.57 535 332 203 
linker.49 HYD 36.43 533 263 270 
hinge.48 ACC 36.29 531 295 236 
hinge.46 HYD 35.13 514 197 317 
hinge.46 ACC 32.13 470 273 197 
g.l.5 HYD 30.14 441 242 199 
c.l.74 HYD 27.89 408 235 173 
b.l.36 HYD 27.55 403 216 187 
g.l.6 HYD 27.41 401 216 185 
αD.55 HYD 26.04 381 140 241 
c.l.75 HYD 24.74 362 254 108 
hinge.48 DON 20.51 300 189 111 
hinge.48 HYD 20.10 294 193 101 
aHYD=hydrophobic, FF= face-face π-stacking, DON= H-bond donor, ACC= H-bond acceptor 
 
Identification of scaffold hops 
Using the same strategy outlined above, it was possible to identify pairs of compounds that 
have different chemical structures but similar protein-ligand interactions and similar potency. 
These pairs of compounds are the so-called scaffold hops as the ones presented in Figure 5. 
Despite the fact that region I in the SAIS maps contains around 40% of the data points, only a 
few of them (< 7%) have an interaction similarity above the thresholds previously defined (see 
Table 2 and the Methods section). This is not surprising taking into account the large size of 
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kinase ATP binding site and the different binding conformation that the inhibitors may have. The 
analysis of scaffold hops helps to identify conserved interactions that are important for the 
activity across many kinases to gain promiscuity and also to identify compounds that might bind 
to a different kinase with similar potency. 
In the examples shown in Figure 5, compounds represented by the same data point form 
similar hydrogen bonds with amino acids at the same positions in both targets. Interestingly, 
most of the hydrogen bonds are formed with the amino acid backbone or with very conserved 
amino acids suggesting that these similar interactions can also be formed with other kinases. 
Remarkably, compounds in the same data pair present conserved hydrophobic interactions 
suggesting that the binding sites in both targets have similar shape. When looking at the 3D 
binding conformation of the compounds extracted from the aligned crystal structure it can be 
observed that the compounds in the same data point overlap to each other, specially at the 
pharmacophoric points involved in the formation of hydrogen bonds (Figure S4).  
Interestingly, from the 878 scaffold hops with similar interaction patterns that were identified 
in the three data sets, only in 325 the two compounds of the data point target the same kinase 
(e.g. Figure 5C). These 325 scaffold hops correspond to only 24 kinases, where CDK2, p38α, 
and CHK1 account for 205, 55 and 11 of them, respectively. In the remaining 553 scaffold hops, 
the two compounds target different kinases with similar potency and presenting similar 
interaction patterns (e.g. Figure 5A and 5B). These cases involve 49 kinases, where CDK2 is 
again the most prevalent target participating in 179 of the 553 data points, followed by KDR and 
MET which take part in 76 and 66, respectively. The most common pairs of kinases are 
CDK2_JNK3 and CDK2_GSK3B, appearing 35 and 20 times, respectively, followed by 
CDK2_JAK2, KDR_MET and KDR_p38α which appear 15 times each. These five pairs of 
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kinases represent the 11% of the 878 scaffold hops with high interaction similarity present in the 
three data sets. It is important to note that the high frequency of CDK2 in these results is 
influenced by the large number of available crystal structures for this protein kinase (namely 257 
in KLIFS of which 216 kinase-ligand complexes).  
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Figure 5. 3D representation and activity data for representative protein-ligand complexes 
identified as scaffold hops, namely (A) 2QD9_3OY1 (11 with p38α67 and 12 with JNK368), (B) 
2QU6_3D83 (13 with VEGFR269 and 14 with p38α70), (C) 2BAK_3GCS (1561  and 1671 with 
p38α). Potency difference, structure (ComboScore/2) and interaction similarity values are shown 
for each molecular pair. Panel D shows the number of interactions between the ligand and each 
of the 85 amino acids in the binding site numbered as defined in KLIFS.27 Per residue, the total 
number of interacting bits is reported and color-coded according to (the combination of) 
interaction feature(s). Figure S4 shows the 2D depiction of these complexes (generated using 
PoseViewWeb 1.97.063, 64) and the superposed 3D structures of these compounds extracted from 
the aligned crystal structure. 
CONCLUSIONS 
This paper discusses the applications and advantages of including molecular interaction 
fingerprints of protein-ligand complexes in activity landscape modelling. To this end, KLIFS27 
was divided in three different data sets, depending on the activity data available (pIC50, pKi, pKd) 
in the MOAD database. The activity landscape of each data set was modelled using Structure-
Activity-Interaction Similarity (SAIS) maps, which show the relationships between ligands 3D 
binding conformation, how they interact with the target, and the resulting biological activity. In 
general, the compounds in this study presented low structural and interaction similarity (ranging 
from 0.366 to 0.383 and from 0.384 to 0.425, respectively) accompanied by large potency 
differences (up to 7.5 log units of difference). It is noteworthy that only less than 6% of the data 
points of each data set presented high interaction similarity.  
The use of IFPs did not only facilitate the structure-based interpretation of activity cliffs, but 
also allowed the identification of the “interaction cliffs” which are introduced in this work as 
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pairs of compounds that have a high (3D and/or 2D) structural and protein-ligand interaction 
similarity, but a large potency difference. On average, only 25% of the activity cliffs were also 
considered as interaction cliffs in the three datasets. Additionally, the information extracted from 
IFPs allowed the identification of activity cliff hot spots, where the hydrophobic contacts with 
the KIII.17 and DxDFG.81 and the face-face interaction with Fhinge.47 seem to be involved in the 
formation of activity cliffs. Also, it was possible to identify scaffold hops with similar protein-
ligand interactions and similar potency. Only less than 7% of compounds with similar potency 
but different molecular structure presented high interaction similarity.  
Taken the results together, this paper shows that the added information given by the interaction 
fingerprints is very valuable to understand and rationalize activity cliffs from both the ligand and 
target point of view. However, the use of IFPs in activity landscape modelling is not restricted to 
the SAIS maps, and this opens up interesting perspectives and challenges. For example, the 
information encoded by IFPs can be incorporated in other activity landscape methods, either 
quantitative (e.g. SALI72 and SARI73) or qualitative, or in the activity landscape modelling of 
other data sets with structural information as the one used by Desaphy et al.21 In conclusion, IFPs 
represent a useful technique to extract valuable information from the ligand-target complex when 
used in the context of activity landscapes.  
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